Literature DB >> 12213570

The c-Jun N-terminal kinases in cerebral microglia: immunological functions in the brain.

Ute Hidding1, Kirsten Mielke, Vicki Waetzig, Stephan Brecht, Uwe Hanisch, Alexander Behrens, Erwin Wagner, Thomas Herdegen.   

Abstract

The c-Jun N-terminal kinases (JNKs) exert a pleiotrophy of physiological and pathological actions. This is also true for the immune system. Disruption of the JNK locus results in substantial functional deficits of peripheral T-cells. In contrast to circulating immune cells and the role of p38, the presence and function of JNKs in the immune cells of the brain remain to be defined. Here, we report on the expression and activation of JNKs in cultivated microglia from neonatal rats and from mice with targeted disruption of the JNK locus and the N-terminal mutation of c-Jun (c-JunAA), respectively. JNK1, 2 and 3 mRNA and proteins were all expressed in microglia. Following stimulation with LPS (100 ng/mL), a classical activator of microglia, JNKs were rapidly activated and this activation returns to basal levels within 4 hr. Following LPS and other stimuli such as thrombin (10-50 unit/mL), the activation of JNKs went along with the N-terminal phosphorylation of c-Jun which persisted for at least 8 hr. Indirect inhibition of JNK by CEP-11004 (0.5-2 microM), an inhibitor of mixed-lineage kinases (MLK), reduced the LPS-induced phosphorylation of both, JNK and c-Jun, by around 50%, and attentuated the LPS-induced the alterations in microglial morphology. Finally, JNKs are involved in the control of cytokine release since both, incubation with CEP-11004 and disruption of the JNK1 locus enhanced the release of TNFalpha, IL-6 and IL-12. Our findings provide insight in so far unknown functions of JNKs in cerebral immune cells. These observations are also important for the wide spread efforts to develop JNK-inhibitors as neuroprotective drugs which, however, might trigger pro-inflammatory processes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12213570     DOI: 10.1016/s0006-2952(02)01139-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  16 in total

Review 1.  Mitochondrial dysfunction and cell death in neurodegenerative diseases through nitroxidative stress.

Authors:  Mohammed Akbar; Musthafa Mohamed Essa; Ghazi Daradkeh; Mohamed A Abdelmegeed; Youngshim Choi; Lubna Mahmood; Byoung-Joon Song
Journal:  Brain Res       Date:  2016-02-13       Impact factor: 3.252

Review 2.  Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases.

Authors:  Marie A Bogoyevitch; Bostjan Kobe
Journal:  Microbiol Mol Biol Rev       Date:  2006-12       Impact factor: 11.056

Review 3.  JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer's and various neurodegenerative abnormalities.

Authors:  Sidharth Mehan; Harikesh Meena; Deepak Sharma; Rameshwar Sankhla
Journal:  J Mol Neurosci       Date:  2010-09-28       Impact factor: 3.444

Review 4.  Neuropharmacologic Approaches to Restore the Brain's Microenvironment.

Authors:  Weizhe Li; Hsin-I Tong; Santhi Gorantla; Larisa Y Poluektova; Howard E Gendelman; Yuanan Lu
Journal:  J Neuroimmune Pharmacol       Date:  2016-06-28       Impact factor: 4.147

5.  Low-density lipoprotein receptors regulate microglial inflammation through c-Jun N-terminal kinase.

Authors:  Ana Pocivavsek; Mark P Burns; G William Rebeck
Journal:  Glia       Date:  2009-03       Impact factor: 7.452

6.  Inhibition of c-Jun N-terminal kinase increases apoE expression in vitro and in vivo.

Authors:  Ana Pocivavsek; G William Rebeck
Journal:  Biochem Biophys Res Commun       Date:  2009-07-15       Impact factor: 3.575

7.  LPS-induced indoleamine 2,3-dioxygenase is regulated in an interferon-gamma-independent manner by a JNK signaling pathway in primary murine microglia.

Authors:  Yunxia Wang; Marcus A Lawson; Robert Dantzer; Keith W Kelley
Journal:  Brain Behav Immun       Date:  2009-07-03       Impact factor: 7.217

8.  Loss of MLK3 signaling impedes ulcer healing by modulating MAPK signaling in mouse intestinal mucosa.

Authors:  Pavlo L Kovalenko; Lyudmyla Kunovska; Jian Chen; Kathleen A Gallo; Marc D Basson
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-08-23       Impact factor: 4.052

9.  JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease.

Authors:  Stéphane Hunot; Miquel Vila; Peter Teismann; Roger J Davis; Etienne C Hirsch; Serge Przedborski; Pasko Rakic; Richard A Flavell
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-02       Impact factor: 11.205

10.  Early steps of microglial activation are directly affected by neuroprotectant FK506 in both in vitro inflammation and in rat model of stroke.

Authors:  Malgorzata Zawadzka; Michal Dabrowski; Agata Gozdz; Barbara Szadujkis; Marcin Sliwa; Maciej Lipko; Bozena Kaminska
Journal:  J Mol Med (Berl)       Date:  2012-07-18       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.